Targeted thermosensitive liposomes: an attractive novel approach for increased drug delivery to solid tumors

Bibliography

• Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 2013;65(1):36-48
   PubMed Web of Science ®Google Scholar
• Koning GA, Krijger GC. Targeted multifunctional lipid-based nanocarriers for image-guided drug delivery. Anticancer Agents Med Chem 2007;7(4):425-40
   PubMed Web of Science ®Google Scholar
• Charrois GJ, Allen TM. Rate of biodistribution of STEALTH liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity. Biochim Biophys Acta 2003;1609(1):102-8
   PubMed Web of Science ®Google Scholar
• Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000;65(1-2):271-84
   PubMed Web of Science ®Google Scholar
• Hobbs SK, Monsky WL, Yuan F, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 1998;95(8):4607-12
   PubMed Web of Science ®Google Scholar
• Prabhakar U, Maeda H, Jain RK, et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res 2013;73(8):2412-17
   PubMed Web of Science ®Google Scholar
• Harrington KJ, Mohammadtaghi S, Uster PS, et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 2001;7(2):243-54
   PubMed Web of Science ®Google Scholar
• Seynhaeve AL, Hoving S, Schipper D, et al. Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response. Cancer Res 2007;67(19):9455-62
   PubMed Web of Science ®Google Scholar
• O'Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15(3):440-9
   PubMed Web of Science ®Google Scholar
• Mills JK, Needham D. The materials engineering of temperature-sensitive liposomes. Methods Enzymol 2004;387:82-113
   PubMed Web of Science ®Google Scholar
• Needham D, Anyarambhatla G, Kong G, Dewhirst MW. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res 2000;60(5):1197-201
   PubMed Web of Science ®Google Scholar
• Tsong TY. Kinetics of the crystalline-liquid crystalline phase transition of dimyristoyl L-alpha-lecithin bilayers. Proc Natl Acad Sci USA 1974;71(7):2684-8
   PubMed Web of Science ®Google Scholar
• Park JW, Hong K, Kirpotin DB, et al. Immunoliposomes for cancer treatment. Adv Pharmacol 1997;40:399-435
   PubMedGoogle Scholar
• Fretz MM, Hogset A, Koning GA, et al. Cytosolic delivery of liposomally targeted proteins induced by photochemical internalization. Pharma Res 2007;24(11):2040-7
   Google Scholar
• Gaber MH. Modulation of doxorubicin resistance in multidrug-resistance cells by targeted liposomes combined with hyperthermia. J Biochem Mol Biol Biophys 2002;6(5):309-14
   PubMedGoogle Scholar
• Kullberg M, Mann K, Owens JL. A two-component drug delivery system using Her-2-targeting thermosensitive liposomes. J Drug Target 2009;17(2):98-107
   PubMed Web of Science ®Google Scholar
• Kullberg M, Owens JL, Mann K. Listeriolysin O enhances cytoplasmic delivery by Her-2 targeting liposomes. J Drug Target 2010;18(4):313-20
   PubMed Web of Science ®Google Scholar
• Puri A, Kramer-Marek G, Campbell-Massa R, et al. HER2-specific affibody-conjugated thermosensitive liposomes (Affisomes) for improved delivery of anticancer agents. J Liposome Res 2008;18(4):293-307
   PubMed Web of Science ®Google Scholar
• Dicheva BM, Hagen TL, Li L, et al. Cationic thermosensitive liposomes: a novel dual targeted heat-triggered drug delivery approach for endothelial and tumor Cells. Nano Lett 2013;13(6):2324-31
   PubMed Web of Science ®Google Scholar
• Negussie AH, Miller JL, Reddy G, et al. Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome. J Control Release 2010;143(2):265-73
   PubMed Web of Science ®Google Scholar
• Smith B, Lyakhov I, Loomis K, et al. Hyperthermia-triggered intracellular delivery of anticancer agent to HER2(+) cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2(+) affisomes). J Control Release 2011;153(2):187-94
   PubMed Web of Science ®Google Scholar
• Reinhold HS, van der Zee J, Faithfull NS, et al. Use of the Pomp-Siemens hyperthermia cabin. Natl Cancer Inst Monogr 1982;61:371-5
   PubMedGoogle Scholar
• Grull H, Langereis S. Hyperthermia-triggered drug delivery from temperature-sensitive liposomes using MRI-guided high intensity focused ultrasound. J Control Release 2013 Jul 20;161(2):317-27
   Web of Science ®Google Scholar
• Peller M, Schwerdt A, Hossann M, et al. MR characterization of mild hyperthermia-induced gadodiamide release from thermosensitive liposomes in solid tumors. Investig Radiol 2008;43(12):877-92
   PubMed Web of Science ®Google Scholar
• Tagami T, Foltz WD, Ernsting MJ, et al. MRI monitoring of intratumoral drug delivery and prediction of the therapeutic effect with a multifunctional thermosensitive liposome. Biomaterials 2011;32(27):6570-8
   PubMed Web of Science ®Google Scholar
• Viglianti BL, Ponce AM, Michelich CR, et al. Chemodosimetry of in vivo tumor liposomal drug concentration using MRI. Magn Reson Med 2006;56(5):1011-18
   PubMed Web of Science ®Google Scholar
• de Smet M, Heijman E, Langereis S, et al. Magnetic resonance imaging of high intensity focused ultrasound mediated drug delivery from temperature-sensitive liposomes: an in vivo proof-of-concept study. J Control Release 2013;150(1):102-10
   Web of Science ®Google Scholar
• Ranjan A, Jacobs GC, Woods DL, et al. Image-guided drug delivery with magnetic resonance guided high intensity focused ultrasound and temperature sensitive liposomes in a rabbit Vx2 tumor model. J Control Release 2012;158(3):487-94
   PubMed Web of Science ®Google Scholar
• Stakhursky VL, Arabe O, Cheng KS, et al. Real-time MRI-guided hyperthermia treatment using a fast adaptive algorithm. Phys Med Biol 2009;54(7):2131-45
   PubMed Web of Science ®Google Scholar
• Song CW, Shakil A, Griffin RJ, Okajima K. Improvement of tumor oxygenation status by mild temperature hyperthermia alone or in combination with carbogen. Semin Oncol 1997;24(6):626-32
   PubMed Web of Science ®Google Scholar
• de Bruijne M, Wielheesen DH, van der Zee J, et al. Benefits of superficial hyperthermia treatment planning: five case studies. Int J Hyperthermia 2007;23(5):417-29
   PubMed Web of Science ®Google Scholar
• Franckena M, Canters R, Termorshuizen F, et al. Clinical implementation of hyperthermia treatment planning guided steering: a cross over trial to assess its current contribution to treatment quality. Int J Hyperthermia 2010;26(2):145-57
   PubMed Web of Science ®Google Scholar
• Horsman MR, Overgaard J. Hyperthermia: a potent enhancer of radiotherapy. Clin Oncol (R Coll Radiol) 2007;19(6):418-26
   PubMed Web of Science ®Google Scholar
• Van Der Zee J, De Bruijne M, Mens JW, et al. Reirradiation combined with hyperthermia in breast cancer recurrences: overview of experience in Erasmus MC. Int J Hyperthermia 2010;26(7):638-48
   PubMed Web of Science ®Google Scholar
• van der Zee J, Gonzalez Gonzalez D, van Rhoon GC, et al. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet 2000;355(9210):1119-25
   PubMed Web of Science ®Google Scholar
• van der Zee J, van Rhoon GC. Cervical cancer: radiotherapy and hyperthermia. Int J Hyperthermia 2006;22(3):229-34
   PubMed Web of Science ®Google Scholar
• Colombo R, Da Pozzo LF, Salonia A, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol 2003;21(23):4270-6
   PubMed Web of Science ®Google Scholar
• Issels RD, Lindner LH, Verweij J, et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol 2010;11(6):561-70
   PubMed Web of Science ®Google Scholar
• Urano M, Kuroda M, Nishimura Y. For the clinical application of thermochemotherapy given at mild temperatures. Int J Hyperthermia 1999;15(2):79-107
   PubMed Web of Science ®Google Scholar
• al-Shabanah OA, Osman AM, al-Harbi MM, et al. Enhancement of doxorubicin-induced cytotoxicity by hyperthermia in Ehrlich ascites cells. Chemotherapy 1994 May-Jun;40(3):188-94
   PubMed Web of Science ®Google Scholar
• Hildebrandt B, Wust P, Ahlers O, et al. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol 2002;43(1):33-56
   PubMed Web of Science ®Google Scholar
• Urano M, Begley J, Reynolds R. Interaction between adriamycin cytotoxicity and hyperthermia: growth-phase-dependent thermal sensitization. Int J Hyperthermia 1994;10(6):817-26
   PubMed Web of Science ®Google Scholar
• Eppink B, Krawczyk PM, Stap J, Kanaar R. Hyperthermia-induced DNA repair deficiency suggests novel therapeutic anti-cancer strategies. Int J Hyperthermia 2012;28(6):509-17
   PubMed Web of Science ®Google Scholar
• Kampinga HH, Dikomey E. Hyperthermic radiosensitization: mode of action and clinical relevance. Int J Radiat Biol 2001;77(4):399-408
   PubMed Web of Science ®Google Scholar
• Krawczyk PM, Eppink B, Essers J, et al. Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition. Proc Natl Acad Sci USA 2011;108(24):9851-6
   PubMed Web of Science ®Google Scholar
• Horsman MR, Overgaard J. Can mild hyperthermia improve tumour oxygenation? Int J Hyperthermia 1997;13(2):141-7
   PubMed Web of Science ®Google Scholar
• Karino T, Koga S, Maeta M. Experimental studies of the effects of local hyperthermia on blood flow, oxygen pressure and pH in tumors. Jpn J Surg 1988;18(3):276-83
   PubMedGoogle Scholar
• Hauck ML, Coffin DO, Dodge RK, et al. A local hyperthermia treatment which enhances antibody uptake in a glioma xenograft model does not affect tumour interstitial fluid pressure. Int J Hyperthermia 1997;13(3):307-16
   PubMed Web of Science ®Google Scholar
• Fujiwara K, Watanabe T. Effects of hyperthermia, radiotherapy and thermoradiotherapy on tumor microvascular permeability. Acta Pathol Jpn 1990 Feb;40(2):79-84
   PubMedGoogle Scholar
• Gaber MH, Wu NZ, Hong K, et al. Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks. Int J Radiat Oncol Biol Phys 1996;36(5):1177-87
   PubMed Web of Science ®Google Scholar
• Kong G, Braun RD, Dewhirst MW. Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res 2000;60(16):4440-5
   PubMed Web of Science ®Google Scholar
• Li L, ten Hagen TL, Bolkestein M, et al. Improved intratumoral nanoparticle extravasation and penetration by mild hyperthermia. J Control Release 2013;167(2):130-7
   PubMed Web of Science ®Google Scholar
• Huang SK, Stauffer PR, Hong K, et al. Liposomes and hyperthermia in mice: increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes. Cancer Res 1994;54(8):2186-91
   PubMed Web of Science ®Google Scholar
• Kong G, Braun RD, Dewhirst MW. Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res 2001;61(7):3027-32
   PubMed Web of Science ®Google Scholar
• Matteucci ML, Anyarambhatla G, Rosner G, et al. Hyperthermia increases accumulation of technetium-99m-labeled liposomes in feline sarcomas. Clin Cancer Res 2000;6(9):3748-55
   PubMed Web of Science ®Google Scholar
• May JP, Li SD. Hyperthermia-induced drug targeting. Expert opin Drug Deliv 2013;10(4):511-27
   PubMed Web of Science ®Google Scholar
• Dreher MR, Liu W, Michelich CR, et al. Thermal cycling enhances the accumulation of a temperature-sensitive biopolymer in solid tumors. Cancer Res 2007;67(9):4418-24
   PubMed Web of Science ®Google Scholar
• Moktan S, Perkins E, Kratz F, Raucher D. Thermal targeting of an acid-sensitive doxorubicin conjugate of elastin-like polypeptide enhances the therapeutic efficacy compared with the parent compound in vivo. Mol Cancer Ther 2012;11(7):1547-56
   PubMed Web of Science ®Google Scholar
• Bidwell GL III, Perkins E, Raucher D. A thermally targeted c-Myc inhibitory polypeptide inhibits breast tumor growth. Cancer Lett 2012;319(2):136-43
   PubMed Web of Science ®Google Scholar
• Yatvin MB, Weinstein JN, Dennis WH, Blumenthal R. Design of liposomes for enhanced local release of drugs by hyperthermia. Science 1978;202(4374):1290-3
   PubMed Web of Science ®Google Scholar
• de Smet M, Langereis S, van den Bosch S, Grull H. Temperature-sensitive liposomes for doxorubicin delivery under MRI guidance. J Control Release 2010;143(1):120-7
   PubMed Web of Science ®Google Scholar
• Li L, ten Hagen TL, Schipper D, et al. Triggered content release from optimized stealth thermosensitive liposomes using mild hyperthermia. J Control Release 2010;143(2):274-9
   PubMed Web of Science ®Google Scholar
• Lindner LH, Eichhorn ME, Eibl H, et al. Novel temperature-sensitive liposomes with prolonged circulation time. Clin Cancer Res 2004;10(6):2168-78
   PubMed Web of Science ®Google Scholar
• Gaber MH, Hong K, Huang SK, Papahadjopoulos D. Thermosensitive sterically stabilized liposomes: formulation and in vitro studies on mechanism of doxorubicin release by bovine serum and human plasma. Pharma Res 1995;12(10):1407-16
   Google Scholar
• Unezaki S, Maruyama K, Takahashi N, et al. Enhanced delivery and antitumor activity of doxorubicin using long-circulating thermosensitive liposomes containing amphipathic polyethylene glycol in combination with local hyperthermia. Pharma Res 1994;11(8):1180-5
   Google Scholar
• Landon CD, Park J, Needham D, Dewhirst MW. Nanoscale drug delivery and hyperthermia: the materials design and preclinical and clinical testing of low temperature-sensitive liposomes used in combination with mild hyperthermia in the treatment of local cancer. Open Nanomed J 2011(3):38-64
   Google Scholar
• Mills JK, Needham D. Lysolipid incorporation in dipalmitoylphosphatidylcholine bilayer membranes enhances the ion permeability and drug release rates at the membrane phase transition. Biochim Biophys Acta 2005;1716(2):77-96
   PubMed Web of Science ®Google Scholar
• Manzoor AA, Lindner LH, Landon CD, et al. Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors. Cancer Res 2012;72(21):5566-75
   PubMed Web of Science ®Google Scholar
• Hossann M, Syunyaeva Z, Schmidt R, et al. Proteins and cholesterol lipid vesicles are mediators of drug release from thermosensitive liposomes. J Control Release 2012;162(2):400-6
   PubMed Web of Science ®Google Scholar
• Poon RT, Borys N. Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer. Expert Opin Pharmacother 2009;10(2):333-43
   PubMed Web of Science ®Google Scholar
• Al-Jamal WT, Al-Ahmady ZS, Kostarelos K. Pharmacokinetics & tissue distribution of temperature-sensitive liposomal doxorubicin in tumor-bearing mice triggered with mild hyperthermia. Biomaterials 2012;33(18):4608-17
   PubMed Web of Science ®Google Scholar
• Hossann M, Wang T, Wiggenhorn M, et al. Size of thermosensitive liposomes influences content release. J Control Release 2010;147(3):436-43
   PubMed Web of Science ®Google Scholar
• Li L, Ten Hagen TL, Hossann M, et al. Mild hyperthermia triggered doxorubicin release from optimized stealth thermosensitive liposomes improves intratumoral drug delivery and efficacy. J Control Release 2013;168(2):142-50
   PubMed Web of Science ®Google Scholar
• Tagami T, Ernsting MJ, Li SD. Efficient tumor regression by a single and low dose treatment with a novel and enhanced formulation of thermosensitive liposomal doxorubicin. J Control Release 2011;152(2):303-9
   PubMed Web of Science ®Google Scholar
• Tagami T, Ernsting MJ, Li SD. Optimization of a novel and improved thermosensitive liposome formulated with DPPC and a Brij surfactant using a robust in vitro system. J Control Release 2011 Sep 25;154(3):290-7
   PubMed Web of Science ®Google Scholar
• Tagami T, May JP, Ernsting MJ, Li SD. A thermosensitive liposome prepared with a Cu(2)(+) gradient demonstrates improved pharmacokinetics, drug delivery and antitumor efficacy. J Control Release 2012;161(1):142-9
   PubMed Web of Science ®Google Scholar
• Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem 2010;21(5):797-802
   PubMed Web of Science ®Google Scholar
• Chen Q, Tong S, Dewhirst MW, Yuan F. Targeting tumor microvessels using doxorubicin encapsulated in a novel thermosensitive liposome. Mol Cancer Ther 2004;3(10):1311-17
   PubMed Web of Science ®Google Scholar
• Seynhaeve AL, Eggermont AM, ten Hagen TL. TNF and manipulation of the tumor cell-stromal interface: "ways to make chemotherapy effective". Front Biosci 2008;13:3034-45
   PubMed Web of Science ®Google Scholar
• Ponce AM, Viglianti BL, Yu D, et al. Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects. J Natl Cancer Inst 2007;99(1):53-63
   PubMed Web of Science ®Google Scholar
• Dromi S, Frenkel V, Luk A, et al. Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin Cancer Res 2007;13(9):2722-7
   PubMed Web of Science ®Google Scholar
• Drummond DC, Meyer O, Hong K, et al. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999 Dec;51(4):691-743
   PubMed Web of Science ®Google Scholar
• Mastrobattista E, Koning GA, Storm G. Immunoliposomes for the targeted delivery of antitumor drugs. Adv Drug Deliv Rev 1999;40(1-2):103-27
   PubMed Web of Science ®Google Scholar
• Wicki A, Rochlitz C, Orleth A, et al. Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth. Clin Cancer Res 2012;18(2):454-64
   PubMed Web of Science ®Google Scholar
• Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002;2(10):750-63
   PubMed Web of Science ®Google Scholar
• Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 2004;303(5665):1818-22
   PubMed Web of Science ®Google Scholar
• Kirpotin D, Park JW, Hong K, et al. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 1997;36(1):66-75
   PubMed Web of Science ®Google Scholar
• Park JW, Hong K, Carter P, et al. Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc Natl Acad Sci USA 1995;92(5):1327-31
   PubMed Web of Science ®Google Scholar
• Sapra P, Allen TM. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res 2002;62(24):7190-4
   PubMed Web of Science ®Google Scholar
• Koning GA, Morselt HW, Gorter A, et al. Pharmacokinetics of differently designed immunoliposome formulations in rats with or without hepatic colon cancer metastases. Pharma Res 2001;18(9):1291-8
   Google Scholar
• Koning GA, Morselt HW, Gorter A, et al. Interaction of differently designed immunoliposomes with colon cancer cells and Kupffer cells. An in vitro comparison. Pharma Res 2003;20(8):1249-57
   Google Scholar
• Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 2006;312(5):549-60
   PubMed Web of Science ®Google Scholar
• Koning GA, Schiffelers RM, Storm G. Endothelial cells at inflammatory sites as target for therapeutic intervention. Endothelium 2002;9(3):161-71
   PubMed Web of Science ®Google Scholar
• Drummond DC, Hong K, Park JW, et al. Liposome targeting to tumors using vitamin and growth factor receptors. Vitam Horm 2000;60:285-332
   PubMed Web of Science ®Google Scholar
• Park JW, Hong K, Kirpotin DB, et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 2002;8(4):1172-81
   PubMed Web of Science ®Google Scholar
• Sugano M, Egilmez NK, Yokota SJ, et al. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice. Cancer Res 2000;60(24):6942-9
   PubMed Web of Science ®Google Scholar
• Zhao G, Rodriguez BL. Molecular targeting of liposomal nanoparticles to tumor microenvironment. Int J Nanomedicine 2013;8:61-71
   PubMed Web of Science ®Google Scholar
• Campbell RB, Ying B, Kuesters GM, Hemphill R. Fighting cancer: from the bench to bedside using second generation cationic liposomal therapeutics. J Pharm Sci 2009;98(2):411-29
   PubMed Web of Science ®Google Scholar
• Schiffelers RM, Koning GA, ten Hagen TL, et al. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J Control Release 2003;91(1-2):115-22
   PubMed Web of Science ®Google Scholar
• Pastorino F, Brignole C, Marimpietri D, et al. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res 2003;63(21):7400-9
   PubMed Web of Science ®Google Scholar
• Sapra P, Allen TM. Ligand-targeted liposomal anticancer drugs. Prog Lipid Res 2003;42(5):439-62
   PubMed Web of Science ®Google Scholar
• Loi M, Marchio S, Becherini P, et al. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma. J Control Release 2010;145(1):66-73
   PubMed Web of Science ®Google Scholar
• Moura V, Lacerda M, Figueiredo P, et al. Targeted and intracellular triggered delivery of therapeutics to cancer cells and the tumor microenvironment: impact on the treatment of breast cancer. Breast Cancer Res Treat 2012;133(1):61-73
   PubMed Web of Science ®Google Scholar
• Xiong XB, Huang Y, Lu WL, et al. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. J Control Release 2005;107(2):262-75
   PubMed Web of Science ®Google Scholar
• Zhao H, Wang JC, Sun QS, et al. RGD-based strategies for improving antitumor activity of paclitaxel-loaded liposomes in nude mice xenografted with human ovarian cancer. J Drug Target 2009;17(1):10-18
   PubMed Web of Science ®Google Scholar
• Kalra AV, Campbell RB. Development of 5-FU and doxorubicin-loaded cationic liposomes against human pancreatic cancer: implications for tumor vascular targeting. Pharma Res 2006;23(12):2809-17
   Google Scholar
• Strieth S, Eichhorn ME, Werner A, et al. Paclitaxel encapsulated in cationic liposomes increases tumor microvessel leakiness and improves therapeutic efficacy in combination with Cisplatin. Clin Cancer Res 2008;14(14):4603-11
   PubMed Web of Science ®Google Scholar
• Campbell RB, Fukumura D, Brown EB, et al. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res 2002;62(23):6831-6
   PubMed Web of Science ®Google Scholar
• Ho EA, Ramsay E, Ginj M, et al. Characterization of cationic liposome formulations designed to exhibit extended plasma residence times and tumor vasculature targeting properties. J Pharm Sci 2010;99(6):2839-53
   PubMed Web of Science ®Google Scholar
• Abu Lila AS, Kizuki S, Doi Y, et al. Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model. J Control Release 2009;137(1):8-14
   PubMed Web of Science ®Google Scholar
• Schmitt-Sody M, Strieth S, Krasnici S, et al. Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. Clin Cancer Res 2003;9(6):2335-41
   PubMed Web of Science ®Google Scholar
• Wu J, Lee A, Lu Y, Lee RJ. Vascular targeting of doxorubicin using cationic liposomes. Int J Pharm 2007;337(1-2):329-35
   PubMedGoogle Scholar
• Mamot C, Drummond DC, Greiser U, et al. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res 2003;63(12):3154-61
   PubMed Web of Science ®Google Scholar
• Mamot C, Drummond DC, Noble CO, et al. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res 2005;65(24):11631-8
   PubMed Web of Science ®Google Scholar
• Mamot C, Ritschard R, Wicki A, et al. Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. Lancet Oncol 2012;13(12):1234-41
   PubMed Web of Science ®Google Scholar
• Lundberg BB, Griffiths G, Hansen HJ. Cellular association and cytotoxicity of doxorubicin-loaded immunoliposomes targeted via Fab' fragments of an anti-CD74 antibody. Drug Deliv 2007;14(3):171-5
   PubMed Web of Science ®Google Scholar
• Brignole C, Marimpietri D, Gambini C, et al. Development of Fab' fragments of anti-GD(2) immunoliposomes entrapping doxorubicin for experimental therapy of human neuroblastoma. Cancer Lett 2003;197(1-2):199-204
   PubMed Web of Science ®Google Scholar
• Weinstein JN, Eger RR, Covell DG, et al. The pharmacology of monoclonal antibodies. Ann NY Acad Sci 1987;507:199-210
   PubMed Web of Science ®Google Scholar
• Mastrobattista E, Koning GA, van Bloois L, et al. Functional characterization of an endosome-disruptive peptide and its application in cytosolic delivery of immunoliposome-entrapped proteins. J Biol Chem 2002;277(30):27135-43
   PubMed Web of Science ®Google Scholar
• Simoes S, Moreira JN, Fonseca C, et al. On the formulation of pH-sensitive liposomes with long circulation times. Adv Drug Deliv Rev 2004;56(7):947-65
   PubMed Web of Science ®Google Scholar
• Fattahi H, Laurent S, Liu F, et al. Magnetoliposomes as multimodal contrast agents for molecular imaging and cancer nanotheragnostics. Nanomedicine (Lond) 2011;6(3):529-44
   PubMed Web of Science ®Google Scholar
• Pradhan P, Giri J, Rieken F, et al. Targeted temperature sensitive magnetic liposomes for thermo-chemotherapy. J Control Release 2010 Feb 25;142(1):108-21
   PubMed Web of Science ®Google Scholar
• Kikumori T, Kobayashi T, Sawaki M, Imai T. Anti-cancer effect of hyperthermia on breast cancer by magnetite nanoparticle-loaded anti-HER2 immunoliposomes. Breast cancer Res Treat 2009;113(3):435-41
   Google Scholar